-
公开(公告)号：US07247488B2
公开(公告)日：2007-07-24
申请号：US10430623
申请日：2003-05-06
IPC分类号： G01N33/86
CPC分类号： G01N33/86 , G01N33/96 , Y10T436/10
摘要： A method and kit for testing a multi-channel blood-testing cartridge. In particular, blood-testing cartridges are tested with plasma samples with clotting times measured to indicate whether a batch of cartridges is suitable for testing the blood of a patient.
摘要翻译： 用于测试多通道血液测试盒的方法和试剂盒。 特别地，用血浆样品测试血液测试盒，其中测量凝固时间以指示一批筒是否适于测试患者的血液。
-
公开(公告)号：US08124025B2
公开(公告)日：2012-02-28
申请号：US11520338
申请日：2006-09-13
申请人： Jyotsna Ghai , Charlene X. Yuan , Wei Qin , Mark A. Thompson
发明人： Jyotsna Ghai , Charlene X. Yuan , Wei Qin , Mark A. Thompson
IPC分类号： G01N21/75
CPC分类号： G01N33/86 , G01N33/4905 , G01N33/54306
摘要： Articles for testing a coagulation process in whole blood.
摘要翻译： 用于测试全血凝血过程的物品。
-
公开(公告)号：US09445990B2
公开(公告)日：2016-09-20
申请号：US13252745
申请日：2011-10-04
申请人： Deanna S. Lane , Charlene X. Yuan , Jianwei Li , Lanchi T. Le
发明人： Deanna S. Lane , Charlene X. Yuan , Jianwei Li , Lanchi T. Le
CPC分类号： A61K9/0019 , A61K47/26
摘要： A formulation for use in an implantable infusion device includes between about 5 mg/ml and about 500 mg/ml (e.g., about 10-25 mg/ml) of a TNF inhibitor polypeptide, 10 mM-25 mM of a phosphate or citrate buffer, has an ionic strength of the combined buffer and an optional salt of the equivalent of about 0.1-0.2 NaCl (e.g., about 0.15 M), 5% to 10% of a carbohydrate (e.g., trehalose or sucrose), has a pH of between 6 and 7, is fluid at room temperature and at 37° C., and has a viscosity of less than about 10 centipoise (e.g., between about 1 centipoise and 9 centipoise, between about 1 cp and about 5 cp, between about 1 cp and about 3 cp, or between about 1 cp and about 2.5 cp) at room temperature.
摘要翻译： 用于可植入输注装置的制剂包括约5mg / ml至约500mg / ml（例如约10-25mg / ml）的TNF抑制剂多肽，10mM -25mM磷酸盐或柠檬酸盐缓冲液 具有组合缓冲液的离子强度和等同于约0.1-0.2NaCl（例如约0.15M），5％至10％的碳水化合物（例如海藻糖或蔗糖）的任选的盐的pH为 在6和7之间，在室温和37℃下是流体，并且具有小于约10厘泊的粘度（例如，在约1厘泊和9厘泊之间，约1cp和约5cp之间，约1 cp和约3cp，或约1cp至约2.5cp）。
-
4.发明申请公开(公告)号：US20090088818A1
公开(公告)日：2009-04-02
申请号：US12236852
申请日：2008-09-24
IPC分类号： A61N1/36
CPC分类号： A61N1/36007
摘要： The disclosure is directed to gastric stimulation programmers, stimulators and methods for controlling delivery of gastric stimulation therapy to maintain the efficacy of the therapy over time. Maintaining the efficacy of gastric stimulation therapy may be possible by implementing one or more anti-desensitization features in a gastric stimulation controller or stimulator. As electrical stimulation therapy is continuously delivered to a patient, the stimulated tissue may become desensitized to the electrical stimulation therapy such that the beneficial effect of the electrical stimulation is diminished. Once desensitization occurs, the affected tissue may not respond favorably to electrical stimulation therapy. Application of one or more anti-desensitization features to control gastric stimulation therapy may reduce or prevent desensitization and effectively extend the efficacy of the therapy over time.
摘要翻译： 本公开涉及胃刺激程序员，刺激剂和用于控制胃刺激治疗递送的方法，以保持治疗随时间的功效。 通过在胃刺激控制器或刺激器中实施一种或多种抗脱敏特征，可以维持胃刺激治疗的功效。 随着电刺激治疗被持续递送到患者，刺激的组织可能变得对电刺激疗法脱敏，使得电刺激的有益效果减弱。 一旦发生脱敏，受影响的组织可能不会有利于电刺激治疗。 应用一种或多种抗脱敏特征来控制胃刺激疗法可以减少或预防脱敏，并有效地延长治疗的疗效。
-
5.发明授权公开(公告)号：US07983755B2
公开(公告)日：2011-07-19
申请号：US12236924
申请日：2008-09-24
IPC分类号： A61N1/36
CPC分类号： A61N1/36007
摘要： The disclosure is directed to gastric stimulation programmers, stimulators and methods for controlling delivery of gastric stimulation therapy to maintain the efficacy of the therapy over time. Maintaining the efficacy of gastric stimulation therapy may be possible by implementing one or more anti-desensitization features in a gastric stimulation controller or stimulator. As electrical stimulation therapy is continuously delivered to a patient, the stimulated tissue may become desensitized to the electrical stimulation therapy such that the beneficial effect of the electrical stimulation is diminished. Once desensitization occurs, the affected tissue may not respond favorably to electrical stimulation therapy. Application of one or more anti-desensitization features to control gastric stimulation therapy may reduce or prevent desensitization and effectively extend the efficacy of the therapy over time.
摘要翻译： 本公开涉及胃刺激程序员，刺激剂和用于控制胃刺激治疗递送的方法，以保持治疗随时间的功效。 通过在胃刺激控制器或刺激器中实施一种或多种抗脱敏特征，可以维持胃刺激治疗的功效。 随着电刺激治疗被持续递送到患者，刺激的组织可能变得对电刺激疗法脱敏，使得电刺激的有益效果减弱。 一旦发生脱敏，受影响的组织可能不会有利于电刺激治疗。 应用一种或多种抗脱敏特征来控制胃刺激疗法可以减少或预防脱敏，并有效地延长治疗的疗效。
-
6.发明申请GASTRIC ELECTRICAL STIMULATION WITH LOCKOUT INTERVAL ANTI-DESENSITIZATION FEATURE 有权具有锁定间隔抗气孔特征的气路电刺激公开(公告)号：US20090088817A1
公开(公告)日：2009-04-02
申请号：US12236836
申请日：2008-09-24
IPC分类号： A61N1/36
CPC分类号： A61N1/36007
摘要： The disclosure is directed to gastric stimulation programmers, stimulators and methods for controlling delivery of gastric stimulation therapy to maintain the efficacy of the therapy over time. Maintaining the efficacy of gastric stimulation therapy may be possible by implementing one or more anti-desensitization features in a gastric stimulation controller or stimulator. As electrical stimulation therapy is continuously delivered to a patient, the stimulated tissue may become desensitized to the electrical stimulation therapy such that the beneficial effect of the electrical stimulation is diminished. Once desensitization occurs, the affected tissue may not respond favorably to electrical stimulation therapy. Application of one or more anti-desensitization features to control gastric stimulation therapy may reduce or prevent desensitization and effectively extend the efficacy of the therapy over time.
摘要翻译： 本公开涉及胃刺激程序员，刺激剂和用于控制胃刺激治疗递送的方法，以保持治疗随时间的功效。 通过在胃刺激控制器或刺激器中实施一种或多种抗脱敏特征，可以维持胃刺激治疗的功效。 随着电刺激治疗被持续递送到患者，刺激的组织可能变得对电刺激疗法脱敏，使得电刺激的有益效果减弱。 一旦发生脱敏，受影响的组织可能不会有利于电刺激治疗。 应用一种或多种抗脱敏特征来控制胃刺激疗法可以减少或预防脱敏，并有效地延长治疗的疗效。
-
7.发明授权公开(公告)号：US09446234B2
公开(公告)日：2016-09-20
申请号：US12236836
申请日：2008-09-24
IPC分类号： A61N1/36
CPC分类号： A61N1/36007
摘要： The disclosure is directed to gastric stimulation programmers, stimulators and methods for controlling delivery of gastric stimulation therapy to maintain the efficacy of the therapy over time. Maintaining the efficacy of gastric stimulation therapy may be possible by implementing one or more anti-desensitization features in a gastric stimulation controller or stimulator. As electrical stimulation therapy is continuously delivered to a patient, the stimulated tissue may become desensitized to the electrical stimulation therapy such that the beneficial effect of the electrical stimulation is diminished. Once desensitization occurs, the affected tissue may not respond favorably to electrical stimulation therapy. Application of one or more anti-desensitization features to control gastric stimulation therapy may reduce or prevent desensitization and effectively extend the efficacy of the therapy over time.
摘要翻译： 本公开涉及胃刺激程序员，刺激剂和用于控制胃刺激治疗递送的方法，以保持治疗随时间的功效。 通过在胃刺激控制器或刺激器中实施一种或多种抗脱敏特征，可以维持胃刺激治疗的功效。 随着电刺激治疗被持续递送到患者，刺激的组织可能变得对电刺激疗法脱敏，使得电刺激的有益效果减弱。 一旦发生脱敏，受影响的组织可能不会有利于电刺激治疗。 应用一种或多种抗脱敏特征来控制胃刺激疗法可以减少或预防脱敏，并有效地延长治疗的疗效。
-
公开(公告)号：US20120088713A1
公开(公告)日：2012-04-12
申请号：US13252745
申请日：2011-10-04
申请人： Deanna S. Lane , Charlene X. Yuan , Jianwei Li , Lanchi T. Le
发明人： Deanna S. Lane , Charlene X. Yuan , Jianwei Li , Lanchi T. Le
CPC分类号： A61K9/0019 , A61K47/26
摘要： A formulation for use in an implantable infusion device includes between about 5 mg/ml and about 500 mg/ml (e.g., about 10-25 mg/ml) of a TNF inhibitor polypeptide, 10 mM-25 mM of a phosphate or citrate buffer, has an ionic strength of the combined buffer and an optional salt of the equivalent of about 0.1-0.2 NaCl (e.g., about 0.15 M), 5% to 10% of a carbohydrate (e.g., trehalose or sucrose), has a pH of between 6 and 7, is fluid at room temperature and at 37° C., and has a viscosity of less than about 10 centipoise (e.g., between about 1 centipoise and 9 centipoise, between about 1 cp and about 5 cp, between about 1 cp and about 3 cp, or between about 1 cp and about 2.5 cp) at room temperature.
摘要翻译： 用于可植入输注装置的制剂包括约5mg / ml至约500mg / ml（例如约10-25mg / ml）的TNF抑制剂多肽，10mM -25mM磷酸盐或柠檬酸盐缓冲液 具有组合缓冲液的离子强度和等同于约0.1-0.2NaCl（例如约0.15M），5％至10％的碳水化合物（例如海藻糖或蔗糖）的任选的盐的pH为 在6和7之间，在室温和37℃下是流体，并且具有小于约10厘泊的粘度（例如，在约1厘泊和9厘泊之间，约1cp和约5cp之间，约1 cp和约3cp，或约1cp至约2.5cp）。
-
9.发明授权公开(公告)号：US07957807B2
公开(公告)日：2011-06-07
申请号：US12236852
申请日：2008-09-24
IPC分类号： A61N1/18
CPC分类号： A61N1/36007
摘要： The disclosure is directed to gastric stimulation programmers, stimulators and methods for controlling delivery of gastric stimulation therapy to maintain the efficacy of the therapy over time. Maintaining the efficacy of gastric stimulation therapy may be possible by implementing one or more anti-desensitization features in a gastric stimulation controller or stimulator. As electrical stimulation therapy is continuously delivered to a patient, the stimulated tissue may become desensitized to the electrical stimulation therapy such that the beneficial effect of the electrical stimulation is diminished. Once desensitization occurs, the affected tissue may not respond favorably to electrical stimulation therapy. Application of one or more anti-desensitization features to control gastric stimulation therapy may reduce or prevent desensitization and effectively extend the efficacy of the therapy over time.
摘要翻译： 本公开涉及胃刺激程序员，刺激剂和用于控制胃刺激治疗递送的方法，以保持治疗随时间的功效。 通过在胃刺激控制器或刺激器中实施一种或多种抗脱敏特征，可以维持胃刺激治疗的功效。 随着电刺激治疗被持续递送到患者，刺激的组织可能变得对电刺激疗法脱敏，使得电刺激的有益效果减弱。 一旦发生脱敏，受影响的组织可能不会有利于电刺激治疗。 应用一种或多种抗脱敏特征来控制胃刺激疗法可以减少或预防脱敏，并有效地延长治疗的疗效。
-
10.发明申请公开(公告)号：US20090088819A1
公开(公告)日：2009-04-02
申请号：US12236924
申请日：2008-09-24
IPC分类号： A61N1/36
CPC分类号： A61N1/36007
摘要： The disclosure is directed to gastric stimulation programmers, stimulators and methods for controlling delivery of gastric stimulation therapy to maintain the efficacy of the therapy over time. Maintaining the efficacy of gastric stimulation therapy may be possible by implementing one or more anti-desensitization features in a gastric stimulation controller or stimulator. As electrical stimulation therapy is continuously delivered to a patient, the stimulated tissue may become desensitized to the electrical stimulation therapy such that the beneficial effect of the electrical stimulation is diminished. Once desensitization occurs, the affected tissue may not respond favorably to electrical stimulation therapy. Application of one or more anti-desensitization features to control gastric stimulation therapy may reduce or prevent desensitization and effectively extend the efficacy of the therapy over time
摘要翻译： 本公开涉及胃刺激程序员，刺激剂和用于控制胃刺激治疗递送的方法，以保持治疗随时间的功效。 通过在胃刺激控制器或刺激器中实施一种或多种抗脱敏特征，可以维持胃刺激治疗的功效。 随着电刺激治疗被持续递送到患者，刺激的组织可能变得对电刺激疗法脱敏，使得电刺激的有益效果减弱。 一旦发生脱敏，受影响的组织可能不会有利于电刺激治疗。 应用一种或多种抗脱敏特征来控制胃刺激疗法可以减少或防止脱敏，并有效延长治疗的疗效
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.033 秒)
